Maplight Therapeutics, Inc.'s (NASDAQ:MPLT) Quiet Period To End on December 8th

Maplight Therapeutics' (NASDAQ:MPLT - Get Free Report) quiet period is set to expire on Monday, December 8th. Maplight Therapeutics had issued 14,750,000 shares in its IPO on October 27th. The total size of the offering was $250,750,000 based on an initial share price of $17.00. During Maplight Therapeutics' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.Get Maplight Therapeutics alerts:Wall Street Analysts Forecast GrowthMPLT has been the topic of several research reports. Zacks Research upgraded Maplight Therapeutics to a "hold" rating in a research report on Monday, November 24th. Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an "outperform" rating and a $30.00 price objective for the company. Leerink Partnrs raised shares of Maplight Therapeutics to a "strong-buy" rating in a research note on Friday, November 21st. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a "buy" rating and a $28.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued a "buy" rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $31.00.View Our Latest Stock Analysis on MPLTMaplight Therapeutics Stock Up 4.9%Shares of MPLT opened at $13.63 on Monday. Maplight Therapeutics has a 12-month low of $12.24 and a 12-month high of $20.86. About Maplight Therapeutics (Get Free Report)We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.Featured ArticlesFive stocks we like better than Maplight TherapeuticsRussell 2000 Index, How Investors Use it For Profitable TradingWorried About Inflation? These 3 ETFs Offer Real ProtectionBest Energy Stocks - Energy Stocks to Buy NowIntel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally2 Rising CRM Platform Stocks That Can Surge Higher in 2025 Klarna's Crypto Play: A Plan to Fix Its Profit ProblemThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Maplight Therapeutics Right Now?Before you consider Maplight Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maplight Therapeutics wasn't on the list.While Maplight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here